Interpace can now offer the new service alone or in conjunction with ThyGenX next-generation sequencing oncogene panel in New York.
The company's ThyGenX and ThyraMir tests are designed for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
Alere this week informed the New York Stock Exchange in writing of its intention to voluntarily delist its Series B convertible perpetual preferred stock from the exchange.
The agreement, which covers Interpace's ThyGenX and ThyraMIR diagnostic tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
During the quarter, the firm secured payor coverage for its tests with UnitedHealthcare, Premera Blue Cross, and Aetna.
Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.
The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
The company raised net proceeds of $12.2 million, which it will use for various purposes, including working capital and payment of legacy obligations.